Eosinophil‐induced adverse events induced by treatment with programmed cell death 1/ligand 1 inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system
International Journal of Cancer · 2025
DOI: 10.1002/ijc.35398 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Lu Lyu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Diseases, National Clinical Research Cent…. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Eosinophils, B7-H1 Antigen, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Medical and Health Science and Technology Innovation Project of Chinese Academy of Medical Sciences.
Themen: Patientensicherheit
Abstract (Originalsprache)
Eosinophil‐induced adverse events (Eo‐irAEs) have been observed in patients treated with programmed cell death 1/ligand 1 (PD‐1/PD‐L1) inhibitors. Surprisingly, the clinical features and outcomes of Eo‐irAEs induced by PD‐1/PD‐L1 inhibitors have not yet been elucidated. This study investigated the characteristics of and risk factors for Eo‐irAEs induced by PD‐1/PD‐L1 inhibitors. We extracted data on Eo‐irAEs related to PD‐1/PD‐L1 inhibitors from the FDA Adverse Event Reporting System (FAERS) from 2015 to 2023. Disproportionality and Bayesian analyses were applied for data mining and analysis. A total of 430 Eo‐irAEs induced by PD‐1/PD‐L1 inhibitors were included in this study. Older male patients were found to be at a high risk of developing Eo‐irAEs. Cemiplimab (ROR 2.66 [1.38, 5.13]), nivolumab (ROR 1.82 [1.61, 2.05]), and pembrolizumab (ROR 1.35 [1.13, 1.62]) showed stronger signals than the other drugs. Cemiplimab showed higher signals for Eo‐irAEs than other PD‐1/PD‐L1 inhibitors, with an information component (IC) of 1.41 (IC 0.25:0.73). Patients experienced Eo‐irAEs within the first 100 days, with a median onset time of 56 (interquartile range: 17.0–169.0) days. Eo‐irAEs were more likely to occur in patients with lung ( n = 147, 34.83%) and skin tumors ( n = 145, 34.36%). Eosinophilia ( n = 193, 44.88%), drug reactions with eosinophilia and systemic symptoms (DRESS) ( n = 98, 22.79%), and eosinophilic fasciitis ( n = 69, 16.05%) were the most common adverse events. Eo‐irAEs that were life‐threatening or resulted in death comprised 5.15% ( n = 21) and 5.39% ( n = 22) of the patients. PD‐1/PD‐L1 inhibitors used across a broad spectrum of cancers are associated with an increased risk of Eo‐irAEs, which tend to occur early. Although these complications are rare, clinicians using PD‐1/PD‐L1 inhibitors should be aware of and monitor these potentially serious adverse events related to Eo‐irAEs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical Col…
- Department of Pharmacy, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
- State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
- School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Macau, China.
ORCID-Profile: Kai Guan
Förderung
- National Natural Science Foundation of China
- Medical and Health Science and Technology Innovation Project of Chinese Academy of Medical Sciences
Zitieren
APA
Lyu, L., Bian, S., Guan, K., & Zhao, B. (2025). Eosinophil‐induced adverse events induced by treatment with programmed cell death 1/ligand 1 inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system. International Journal of Cancer. https://doi.org/10.1002/ijc.35398
Vancouver
Lyu L, Bian S, Guan K, Zhao B. Eosinophil‐induced adverse events induced by treatment with programmed cell death 1/ligand 1 inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system. International Journal of Cancer. 2025. doi:10.1002/ijc.35398
BibTeX
@article{Lyu2025,
author = {Lyu, Lu and Bian, Sainan and Guan, Kai and Zhao, Bin},
title = {Eosinophil‐induced adverse events induced by treatment with programmed cell death 1/ligand 1 inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.35398}
}
EUVIMED